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Docetaxel plus cisplatin and docetaxel plus irinotecan are active and well-tolerated chemotherapy regimens for advanced non-small-
cell lung cancer (NSCLC). A randomised phase II study compared their efficacy and toxicity in 108 patients with stage IIIb/IV NSCLC,
who were randomised to receive docetaxel 60mgm
 2 and cisplatin 80mgm
 2 on day 1 (DC; n¼51), or docetaxel 60mgm
 2 on
day 8 and irinotecan 60mgm
 2 on day 1 and 8 (DI; n¼57) every 3 weeks. Response rates were 37% for DC and 32% for DI
patients. Median survival times and 1- and 2-year survival rates were 50 weeks (95% confidence interval: 34–78 weeks), 47 and 25%
for DC, and 46 weeks (95% confidence interval: 37–54 weeks), 40 and 18% for DI, respectively. The progression-free survival time
was 20 weeks (95% confidence interval: 14–25 weeks) with DC and 18 (95% confidence interval: 12–22 weeks) with DI.
Significantly more DI than DC patients had grade 4 leucopenia and neutropenia (Po0.01); more DC patients had grade X2
thrombocytopenia (Po0.01). Nausea and vomiting was more pronounced with DC (Po0.01); diarrhoea was more common with DI
(P¼0.01). Three treatment-related deaths occurred in DC patients. In conclusion, although the DI and DC regimens had different
toxicity profiles, there was no significant difference in survival.
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Unfortunately, non-small-cell lung cancer (NSCLC) is a member of
the group of neoplastic diseases that is relatively chemoresistant.
Recent meta-analyses show that cisplatin-based chemotherapy
improves survival (Non-Small Cell Lung Cancer Collaborative
Group, 1995), and it is considered a standard treatment for
NSCLC, Most cisplatin-based regimens have substantial toxicities
that require close monitoring and supportive care. Thus, there is a
need to develop active and less toxic chemotherapy regimens that
include new active compounds with novel mechanisms of action.
In the 1990s, several new, active therapies with single-agent
response rates of 15–30% became available for NSCLC, including
irinotecan, docetaxel, paclitaxel, vinorelbine, and gemcitabine.
Because irinotecan and docetaxel were approved for NSCLC earlier
than the other drugs in Japan, development of regimens containing
irinotecan or docetaxel is more advanced. Docetaxel 60mgm
 2
showed good antitumour activity against advanced NSCLC
(Kunitoh et al, 1996), and the combination of docetaxel plus
cisplatin (DC) is one of the most effective regimens for advanced
NSCLC (Rodriguez et al, 2001; Schiller et al, 2002). Studies in
Japan included a phase II study in which DC yielded a response
rate of 42% (Okamoto et al, 2002), and a phase III study in which
DC was associated with better survival than the vindesine and
cisplatin (VC) combination (Kubota et al, 2002).
Irinotecan demonstrated activity similar to that of VC in stage
IIIb/IV NSCLC (Negoro et al, 2003), and significant longer overall
survival time than VC in stage IV NSCLC (Fukuoka et al, 2000).
We reported a phase I study of docetaxel plus irinotecan (DI) in
patients with advanced NSCLC, in which a promising response rate
of 48% and the median survival time of 48 weeks were achieved
with acceptable toxicities (Masuda et al, 2000). Thus, DI appeared
to be a promising non-cisplatin-containing regimen.
Based on the above findings, we conducted a randomised trial of
DC vs DI in patients with advanced NSCLC to compare the
respective response rates, survival data, and toxicity profiles of the
two regimens. This was a multicentred phase II study.
PATIENTS AND METHODS
Patients
Patients enrolled in this trial had histologically or cytologically
confirmed stage IIIb or IV NSCLC. Patients with stage IIIb disease
who were not candidates for thoracic radiation and patients with
stage IV disease were eligible if they had not received previous
therapy, had measurable disease, and had a life expectancy of at
least 3 months. Additional entry criteria were age X20 years,
performance status of 0 or 1 on the Eastern Cooperative Oncology
Group (ECOG) scale, adequate bone marrow function (leucocyte
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lcount 4000–12000ml
 1, haemoglobin concentration X9.5gdl
 1
platelet count X100000ml
 1), kidney function (creatinine p
upper limit of normal, 24-h creatinine clearance X60mlmin
 1),
liver function (aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) p2.0 times the upper limit of normal,
total bilirubin p1.5mgdl
 1), and pulmonary function (PaO2X60
torr). Patients with active concomitant or a recent (o3 years)
history of any malignancy, symptomatic brain metastases, past
history of drug allergy reactions, complication by interstitial
pneumonia, watery diarrhoea, ileus, treatment with nonsteroidal
anti-inflammatory drugs, or other serious complications, such as
uncontrolled angina pectoris, myocardial infarction within 3
months, heart failure, uncontrolled diabetes mellitus or hyperten-
sion, massive pleural effusion or ascites, or serious active infection
were excluded. All patients gave written informed consent, and the
institutional review board for human experimentation approved
the protocol.
Study evaluations
Pretreatment studies included a complete medical history and
physical examination, chest X-ray, electrocardiography, computed
tomography (CT) scan of the brain and chest, CT or ultrasound
examination of the abdomen, and bone scintigraphy. Blood and
blood chemistry studies included complete blood cell count, liver
function test, serum electrolytes, serum creatinine, and blood urea
nitrogen. Chest X-ray, blood and blood chemistry analyses, and
urinalysis were repeated weekly.
Randomisation and treatment schedule
Patients were randomly assigned to receive the DC regimen or the
DI regimen by a minimisation method using stage (IIIB/IV) and
treatment institution. The DC regimen was consisting of docetaxel
60mgm
 2 on day 1 and cisplatin 80mgm
 2 on day 1, and the DI
regimen was consisting of docetaxel 60mgm
 2 as a 60-min
intravenous infusion on day 8 and irinotecan 60mgm
 2 as a 90-
min intravenous infusion on days 1 and 8 (Figure 1). Both
regimens were repeated every 3 weeks. Participating researchers at
each institution decided the amount of fluid replacement and the
type of antiemetic therapy to administer. Standard antiemetic
treatment in the DC arm consisted of 5-HT3 receptor antagonist
plus 16mg dexamethasone intravenously on day 1, before cisplatin
administration. In the DI arm, standard antiemetic treatment
consisted of 5-HT3 receptor antagonist intravenously before
chemotherapy administration on days 1 and 8. Patients received
at least two treatment cycles, and those with a complete or partial
response after two cycles had treatment continued until there was
evidence of disease progression, intolerable toxicity, or patient
refusal.
Dose modifications
Toxicity assessment was based on the National Cancer Institute–
Common Toxicity Criteria version 2.0. Dose levels and treatment
schedule were modified to avoid severe adverse effects. Patients
receiving DI had the day-8 docetaxel and irinotecan doses
postponed to day 15 if any of the following toxicities was present
on day 8: leucocyte count o3000ml
 1, platelet count
o100000ml
 1 diarrhoea consisting of bloody or watery stools,
or increased to two or more diarrhoea within 24h, abdominal pain
rated mild or worse, hepatic toxicity Xgrade 3, or fever 4381C. If
these toxicities occurred on day 15 after skipping the day-8
treatment, DI was stopped in that course.
Patients could receive the next treatment course only if the
following criteria were met: leucocyte count X4000ml
 1, platelet
count X100000ml
 1 AST/ALT o2.0 times the upper limit of
normal, total bilirubin p1.5mgdl
 1 serum creatinine p the
upper limit of normal, ECOG PSp2, neurotoxicity pgrade 1, no
diarrhoea or oedema. However, if more than 6 weeks passed before
these criteria were satisfied, the patient was removed from the
study.
Dose modification criteria for each drug are shown in Table 1. If
during the previous course, grade 4 leucopenia, grade 4
neutropenia lasting X3 days, or grade 4 thrombocytopenia had
occurred, doses of all drugs were reduced by 10mgm
 2. Doses of
both cisplatin and docetaxel were reduced by 10mgm
 2 in
subsequent cycles if chemotherapy induced grade X2 neurotoxi-
city. Moreover, dose of docetaxel was reduced by 10mgm
 2 if
grade X2 hepatic toxicity or grade X3 stomatitis had occurred.
Dose of cisplatin was reduced by 20/mg/m
2 if grade X2 renal
toxicity occurred. Dose of irinotecan was reduced by 5mgm
 2 if
grade X2 hepatic toxicity had occurred and by 10mgm
 2 if grade
X2 diarrhoea or cancellation of day-8 treatment had occurred.
Evaluation of response and survival
Tumour response was classified according to World Health
Organization (WHO) criteria (World Health Organization, 1979).
Complete response was defined as complete disappearance of all
measurable and assessable disease for at least 4 weeks, Partial
response was a X50% decrease in the sum of the products of the
two IL largest perpendicular diameters of all measurable tumours
lasting at least 4 weeks and without appearance of any new lesions.
No change was defined as a o50% decrease or a o25% increase
of tumor lesions for at least 4 weeks with no new lesions.
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DC arm: docetaxel/cisplatin
DI arm: docetaxel/irinotecan
Day 18 1 5 22 29
Day 1 8 15 22 29
Docetaxel 60 mg m
−2
Cisplatin 80 mg m
−2
Docetaxel 60 mg m
−2
Irinotecan 60 mg m
−2
Stage IIIb vs IV
Institution
Figure 1 Treatment schema: after stratification by stage and institution,
enrolled patients were randomly allocated to receive docetaxel plus
cisplatin (DC) or docetaxel plus irinotecan (DI).
Table 1 Dose modification criteria
Toxicities in previous
cycle
Decrease in
docetaxel
dose
(mg/m
 2)
Decrease in
cisplatin
dose
(mg/m
 2)
Decrease in
-irinotecan
dose
(mg/m
 2)
Grade 4 neutropenia lasting
X3 days, leucopenia or
thrombocytopenia
10 10 10
Grade X2 neurotoxicity 10 10 —
Grade X2 renal toxicity — 20 —
Grade X2 hepatic toxicity 10 — 5
Grade X3 stomatitis 10 — —
Grade X2 diarrhoea — — 10
Cancellation of day-8
treatment
——1 0
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lProgressive disease was defined as development of new-lesions or
a 25% increase in the sum of the products of the two largest
perpendicular diameters of all measurable tumors. Duration of
response in patients who achieved complete or partial response
was measured from the start of treatment to the date of disease
progression.
Statistical methods
Results of this study were evaluated to determine whether the
docetaxel plus irinotecan combination warranted further assess-
ment in a phase III trial. Thus, this study was designed to conduct
two randomised phase II studies concurrently. We calculated the
number of patients required for each of the two studies based on
the Fleming’s single-stage procedure (Fleming, 1982). In both
studies, we set response rates of 40% as target activity level and
20% as the lowest level of interest with a power of 0.9 at a one-
sided significance level of 0.05. As a result, a total of 100 qualified
patients were to be enrolled, with 50 patients in each treatment
arm. The primary objective was to estimate the response rate to
both regimens, particularly to irinotecan plus docetaxel.
Overall survival and progression-free survival were analysed by
the Kaplan–Meier method. The overall survival was measured
from study entry to death. The progression-free survival was
measured from study entry until the day of the first evidence of
disease progression. If the disease had not progressed by the time
of this analysis, progression-free survival was considered censored
at the time of the analysis. All comparisons between patient
characteristics, response rates, and toxicity incidences were
performed by Pearson’s w
2 contingency table analysis.
RESULTS
Patient characteristics
From October 1998 to August 1999, 108 patients were assigned to
receive DC (n¼51) or DI (n¼57). Baseline patient characteristics
according to treatment arm are shown in Table 2. Patients were
well balanced between the two treatment arms in terms of gender,
age, performance status, disease stage, and histologic subtypes.
There were 23% stage Illb patients and 74% had adenocarcinoma.
All patients were included in the survival evaluation, and all were
assessable for antitumor efficacy and toxicity.
Treatment delivery
Patients in both treatment arms received a median of two
treatment courses. Two or more courses were delivered to 72.5
and 71.9%, and four courses to 17.6 and 19.1% of patients in the
DC and DI arms, respectively. Differences between arms in the
number of chemotherapy courses administered were not statisti-
cally significant.
Response to treatment and survival
There were no complete responses. In the DC arm, 19 patients had
partial responses for an overall response rate of 37% (Table 3).
Among DI patients, 18 had partial responses for an overall
response rate of 32%. The difference in response rate between
arms was not significant (P¼0.55). Progressive disease was noted
in twice as many DI (25%) than DC (12%) patients. Early deaths
within 3 months of treatment initiation occurred in 10% (n¼5) of
DC and 5% (n¼3) of DI patients. The early deaths were treatment-
related (three patients, all in the DC arm) or due to disease
progression (five patients).
Overall and progression-free survival curves for the two
treatment arms are shown in Figures 2 and 3. The median
progression-free survival time was 20 weeks (95% confidence
interval: 14–25 weeks) in the DC arm vs 18 weeks (95% confidence
interval: 12–22 weeks) in the DI arm. Median survival times, 1-
year survival rates, and 2-year survival rates were 50 weeks (95%
confidence interval 34–78 weeks), 47 and 25%, respectively, in the
DC arm, and 46 weeks (95% confidence interval: 37–54 weeks), 40
and 18%, respectively, in the DI arm. No significant differences
were noted between groups in progression-free survival (P¼0.33)
or overall survival (P¼0.50), although there were trends toward
higher 1-year and 2-year survival rates in the DC.
Table 2 Baseline patient characteristics
Docetaxel/
cisplatin
Docetaxel/
irinotecan v
2 text
No. of patients 51 57
Gender Male/female 37/14 38/19 P¼0.537
Age (years) Median 62 60
Range 39–74 42–77
PS 0/1 15/36 15/42 P¼0.830
Histology Adenocarcinoma 36 44 P¼0.520
Squamous cell
carcinoma
13 9
Others 2 4
Disease stage Illb/IV 11/40 14/43 P¼0.820
Brain metastasis (+)/( ) 4/47 11/46 P¼0.086
PS¼performance status.
Table 3 Overall response to docetaxel/cisplatin (DC) or docetaxel/
irinotecan (DI) in patients with stages IIIb/IV non-small-cell lung cancer
Response
DC (n¼51)
No. pts
DI (n¼67)
No. pts
Complete response 0 0
Partial response 19 18
No change 23 25
Progressive disease 6 14
NE (TRD) 3 0
Response rate 37.3%* 31.6%*
95% Confidence intervals 24.1–51.9% 19.9–45.2%
pts¼patients; NE¼not evaluable; TRD¼treatment-related death.
*P¼0.55.
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Figure 2 Overall survival according to treatment group, calculated by
Kaplan–Meier method. Median survival times were 50 weeks for DC
(docetaxel plus cisplatin) and 46 weeks for DI (docetaxel plus irinotecan).
P¼0.50 between treatment groups.
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lSecond-line chemotherapy was administered to 61 patients
(24 DC and 37 DI patients). A total of 22 patients in the DI group
received cisplatin-based second-line chemotherapy and five had
partial responses to this treatment (overall response rate, 23%). In
particular, nine patients were subsequently treated with vinor-
elbine containing regimen and three patients had a partial
response. Only two patients in the DC group received an
irinotecan-containing regimen, one of whom had a partial
response. Concerning as second-line chest irradiation, 8 patients
in the DC group and 13 patients the DI group received.
Toxicity
Haematologic and nonhaematologic toxicities are listed in Tables 4
and 5. Grade 4 leucopenia and neutropenia occurred in a
significantly higher percentage of DI than DC patients (leucopenia
16 vs 4%, Po0.01; neutropenia 61 vs 43%, Po0.01). On the other
hand, there was a higher rate of grade X2 thrombocytopenia in
the DC than in the DI arm (14 vs 0%, Po0.01). Rates of anaemia
(decrease in haemoglobin) and febrile neutropenia were similar in
both groups.
Nonhaematologic toxicities including grade X2 nausea (88 vs
51%, Po0.01), vomiting (39 vs 14%, Po0.01), and renal toxicity
(increased serum creatinine; 12 vs 2%, Po0.01) were significantly
more prevalent in the DC than in the DI arm, respectively. On the
other hand, grade X2 diarrhoea occurred significantly more often
in DI than in DC patients (24 vs 42%, P¼0.01). Other
nonhaematologic toxicities, such as hepatic toxicity and peripheral
neuropathy, were mild and occurred with similar frequency in
both groups.
There were three treatment-related deaths in the DC arm, which
were due to febrile neutropenia and sepsis (one of these patients
also developed perforation of the oesophagus). No treatment-
related deaths occurred in the DI arm. The difference in incidence
of treatment-related deaths was not significant.
DISCUSSION
Results of this randomised phase II study showed that the doublet
chemotherapy regimens DC and DI had comparable activity in
patients with advanced NSCLC. A primary goal of this study was to
determine whether the DI combination should be studied in the
phase III setting. Although there were no differences between DI
and DC–a third-generation cisplatin-containing regimen–in over-
all and progression-free survival, patients who received DI tended
to have lower 1-year and 2-year survival rates. Furthermore,
overall toxicity was not reduced in the DI arm compared with the
DC arm. Leucopenia and neutropenia were the major toxicities in
both groups. As expected, emesis and renal toxicity were more
prevalent in patients receiving DC, and diarrhoea occurred more
frequently with DI.
Cisplatin has played a prominent role in the treatment of
NSCLC, despite a relatively unimpressive single-agent response
rate and a relatively severe toxicity profile. In 1995, the Non-Small
Cell Lung Cancer Collaborative Group published a pivotal meta-
analysis of chemotherapy in lung cancer and demonstrated the
advantage of cisplatin-based regimens over best supportive care
(Non-Small Cell Lung Cancer Collaborative Group, 1995). In the
1990s, third-generation chemotherapeutic agents, including pacli-
taxel, docetaxel, vinorelbine, gemcitabine and irinotecan, were
shown to have higher response rates often coupled with fewer
adverse effects (no renal toxicity, no massive dehydration, less
emesis, etc.) than cisplatin. For example, single-agent paclitaxel
(Ranson et al, 2000), docetaxel (Roszkowski et al, 2000), or
vinorelbine (The Elderly Lung Cancer Vinorelbine Italian Study
Group, 1999) significantly improved survival compared with best
supportive care in patients with advanced NSCLC. Studies of
single-agent gemcitabine (Perng et al, 1997) or irinotecan (Negoro
et al, 2003) demonstrated a survival benefit comparable to that of
second-generation chemotherapy regimens (cisplatin plus vinde-
sine, cisplatin plus etoposide). Based on the above results, we
thought that combination chemotherapy consisting of third-
generation agents might improve outcome for patients with
advanced NSCLC.
Only one published study compared cisplatin-based and
noncisplatin-based regimens that included third-generation
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Figure 3 Progression-free survival according to treatment group,
calculated by Kaplan–Meier method. Median progression-free survival
times were 20 weeks for DC (docetaxel plus cisplatin) and 18 weeks for DI
(docetaxel plus irinotecan). P¼0.33 between treatment groups.
Table 4 Haematologic toxicity: maximum toxicity grade in any course
Docetaxel/
cisplatin (% pts)
Docetaxel/
irinotecan (% pts)
Toxicity/grade 2 3 4 2 3 4
Leucopenia
* 31 43 4 26 40 16
Neutropenia
* 10 31 43 4 23 61
Anaemia 47 10 2 46 7 0
Thrombocytopenia
** 10 4 0 0 0 0
Febrile neutropenia 20 28
pts¼patients.
*Po0.01 for grade 4;
**Po0.01 for the sum of grades 2 and 3.
Table 5 Nonhaematologic toxicity: maximum toxicity grade in any
course
Docetaxel/
cisplatin (% pts)
Docetaxel/
irinotecan (% pts)
Toxicity/grade 2 3 4 2 3 4
Diarrhoea
* 18 6 0 26 12 4
Nausea
* 53 33 0 33 18 0
Vomiting
** 33 2 4 14 0 0
Peripheral neuropathy 2 0 0 2 0 0
AST increase 8 2 2 7 0 2
ALT increase 14 4 0 9 2 2
ALP increase 8 2 0 4 0 0
Creatinine increase
* 10 0 2 0 0 2
pts¼patients; AST¼aspartate aminotransferase; ALT¼alanine aminotransferase;
ALP¼alkaline phosphatase.
*Po0.01 for the sum of grades 2, 3, and 4;
**P¼0.01 for
the sum of grades 2, 3, and 4.
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lagents. Georgoulias et al (2001) conducted a randomised study of
cisplatin plus docetaxel (CD) vs gemcitabine plus docetaxel (GD)
in 441 advanced NSCLC patients. The noncisplatin regimen
provided a comparable response rate (CD 32.4%, GD 30.2%) and
median survival time (CD 10 months, GD 9.5 months) but with less
toxicity. The authors stated that the non-cisplatin GD regimen
would likely be more acceptable to patients based on convenience
of administration. However, several randomized trials reported at
recent international meetings showed slightly shorter survival
times with noncisplatin compared with cisplatin-based combina-
tions. Preliminary results of the EORTC-Lung Cancer Group phase
III study of cisplatin plus paclitaxel vs cisplatin plus gemcitabine vs
paclitaxel plus gemcitabine in 480 patients with advanced NSCLC
revealed superior overall survival and progression-free survival
with the cisplatin-based regimens (Van Meerbeeck et al, 2001).
Moreover, in a recent Italian–Canadian intergroup study of 501
patients comparing gemcitabine plus vinorelbine with cisplatin
plus vinorelbine or gemcitabine, the noncisplatin regimen
provided only short-term and sporadic advantages in some
quality-of-life components, but there were no significant differ-
ences in overall and progression-free survival (Gridelli et al, 2002).
The best known noncisplatin platinum-based chemotherapy
regimen is the paclitaxel plus carboplatin doublet. A Southwest
Oncology Group study compared vinorelbine plus cisplatin with
paclitaxel plus carboplatin. No differences in the overall survival or
quality of life were noted between the two treatment groups, but
toxicity rates were significantly lower in patients who received
paclitaxel plus carboplatin (Chen et al, 2002). Results of a recent
ECOG randomised phase III trial evaluating four platinum-based
chemotherapy regimens showed no significant differences in the
overall survival, while the paclitaxel plus carboplatin combination
was less toxic than cisplatin-based chemotherapy (Schiller et al,
2002). Based on these findings, the paclitaxel plus carboplatin
regimen is considered a standard therapy for previously untreated
patients with advanced NSCLC, with activity comparable to that of
cisplatin-based regimens and better tolerability.
The utility of doublet regimens containing third-generation
chemotherapeutic agents for advanced NSCLC thus needs to be
evaluated against the paclitaxel plus carboplatin combination, and
several such studies were reported or are ongoing. The Hellenic
Cooperative Oncology Group is conducting a phase III randomised
study of paclitaxel plus carboplatin vs paclitaxel plus gemcitabine,
and final results indicate comparable activity, toxicity and total
cost of the two regimens in patients with inoperable NSCLC
(Kosmidis et al, 2002). The Taiwan group conducted a similar
study and found that paclitaxel plus carboplatin and paclitaxel plus
gemcitabine had similar efficacy in the treatment of NSCLC, but
that paclitaxel plus carboplatin was more cost-effective (Chen et al,
2002).
As mentioned in the introductory paragraphs, we conducted a
phase I study of docetaxel plus irinotecan (DI) in patients with
advanced NSCLC, and had a promising response rate of 48% and
median survival time of 48 weeks (Masuda et al, 2000). Although
we recommended docetaxel 50mgm
 2 on day 1 plus irinotecan
50mgm
 2 on days 1, 8, and 15 in the phase I study, more than half
of patients could not receive irinotecan on day 15 because of
haematologic toxicities. Accordingly, the day-15 irinotecan dose
was omitted and the day-2 docetaxel dose moved to day 8 and
increased from 50 to 60mgm
 2 in this randomised phase II trial.
It has been reported that second-line chemotherapy compared
with best supportive care may increase the overall survival in
patients with advanced NSCLC, and more studies in this regard are
needed. In a recent study in which patients received cisplatin-
based chemotherapy followed by docetaxel or supportive care
alone, the median survival was significantly longer in the
docetaxel-treated patients (Shepherd et al, 2000). In our study,
52% of patients were treated with second-line chemotherapy. Of
these, 19 (33%) DI patients received cisplatin-based second-line
chemotherapy, five of whom (26%) responded. Thus, cisplatin-
based chemotherapy is capable of exerting antitumour activity in
patients who have relapsed after having received noncisplatin-
containing regimens.
Only two patients in the DC group received an irinotecan-
containing regimen, one of whom had a partial response. As there
were only two patients, we cannot judge whether irinotecan-
containing regimen is effective for the patients after having
received cisplatin-containing regimen.
In conclusion, docetaxel plus irinotecan combinations may be
reasonable treatment options for NSCLC patients who cannot
tolerate cisplatin. However, as there was no significant difference
in the overall survival and no reduction in overall toxicity, DI has
not improved on results obtained with DC. Thus, we will not select
docetaxel/irinotecan as the experimental regimen in the next phase
III study of first-line treatment of advanced NSCLC.
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